2000
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.Peer-Reviewed Original ResearchConceptsDose of irinotecanElimination of irinotecanDrug AdministrationAdvanced cancerFirst cycle patientsChemotherapy-related toxicityDose of paclitaxelClinical side effectsSequence of administrationBlood cell elementsNonhematologic toxicityReversible neutropeniaFirst doseMost patientsPartial responseCycle patientsDose escalationMild diarrheaPreclinical dataPlasma concentrationsSide effectsIrinotecanPatientsPharmacokinetic parametersWeekly schedule
1997
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/jco.1997.15.1.148.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMaximum-tolerated doseMg/ m2/dDose of topotecanM2/dRefractory cancerDay 1Treatment cyclesDrug-induced DNA fragmentationGrowth factor supportTransfusion of RBCsDose of cyclophosphamideFirst treatment cycleAdministration of cyclophosphamideGranulocyte colony-stimulating factorPharmacokinetics of topotecanClass of agentsColony-stimulating factorBlood cell elementsBolus scheduleNonhematologic toxicityReversible neutropeniaDNA fragmentationFactor supportCombination therapy